Skip to main content
SpringerLink
Log in

The Effects of Blood Pressure and Lipid Control on Kidney Allograft Outcome

  • Current Opinion
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Despite the improvement in short- and long-term kidney allograft survival in recent years, a significant number of grafts are lost because of chronic allograft nephropathy (CAN) or death secondary to cardiovascular disease (CVD). There is growing evidence that both hypertension and hyperlipidemia play important roles in the progression of CAN and CVD in kidney transplant recipients. Large, randomized, controlled studies to determine the optimal target levels for BP and serum lipids, as well as the choice of drug therapy, are lacking. However, based on the available data, we suggest that currently recommended target levels in non-transplant patients should also be used after transplantation. We believe that achieving these target levels for BP and serum lipids are of primary importance, and that the non-lipid-lowering effects of HMG-CoA reductase inhibitors might exert additional benefits in prolonging graft survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342(9): 605–12.

    Article  PubMed  CAS  Google Scholar 

  2. Kasiske BL, Gaston RS, Gourishankar S, et al. Long-term deterioration of kidney allograft function. Am J Transplant 2005 Jun; 5(6): 1405–14.

    Article  PubMed  Google Scholar 

  3. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2004; 41(4 Suppl. 3): I–IV, S1–91.

    Google Scholar 

  4. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 Suppl. 1: S1–S290.

    Google Scholar 

  5. Karthikeyan V, Karpinski J, Nair RC, et al. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant 2004; 4(2): 262–9.

    Article  PubMed  Google Scholar 

  6. Midtvedt K, Neumayer HH. Management strategies for post transplant hypertension. Transplantation 2000; 70(11 Suppl.): SS64–9.

    PubMed  CAS  Google Scholar 

  7. Ligtenberg G, Hene RJ, Blankestijn PJ, et al. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12(2): 368–73.

    PubMed  CAS  Google Scholar 

  8. Budde K, Waiser J, Fritsche L, et al. Hypertension in patients after renal transplantation. Transplant Proc 1997; 29 (1–2): 209–211.

    Google Scholar 

  9. Perez Fontan M, Rodriguez-Carmona A, Garcia Falcon T, et al. Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation. Am J Kidney Dis 1999; 33(1): 21–8.

    Article  PubMed  CAS  Google Scholar 

  10. Textor SC, Canzanello VJ, Taler SJ, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994 Dec; 69(12): 1182–93.

    PubMed  CAS  Google Scholar 

  11. Schwenger V, Zeier M, Ritz E. Hypertension after renal transplantation. Curr Hypertens Rep 2001 Oct; 3(5): 434–9.

    Article  PubMed  CAS  Google Scholar 

  12. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334(1): 13–8.

    Article  PubMed  CAS  Google Scholar 

  13. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123(10): 754–62.

    PubMed  CAS  Google Scholar 

  14. Cheigh JS, Haschemeyer RH, Wang JC, et al. Hypertension in kidney transplant recipients: effect on long-term renal allograft survival. Am J Hypertens 1989; 2 (5 Pt 1): 341–8.

    PubMed  CAS  Google Scholar 

  15. Vianello A, Mastrosimone S, Calconi G, et al. The role of hypertension as a damaging factor for kidney grafts under cyclosporine therapy. Am J Kidney Dis 1993; 21 (5 Suppl. 2): 79–83.

    Google Scholar 

  16. Cosio FG, Dillon JJ, Falkenhain ME, et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int 1995; 47(4): 1136–41.

    Article  PubMed  CAS  Google Scholar 

  17. Cosio FG, Falkenhain ME, Pesavento TE, et al. Relationships between arterial hypertension and renal allograft survival in African-American patients. Am J Kidney Dis 1997; 29(3): 419–27.

    Article  PubMed  CAS  Google Scholar 

  18. Frei U, Schindler R, Wieters D, et al. Pre-transplant hypertension: a major risk factor for chronic progressive renal allograft dysfunction? Nephrol Dial Transplant 1995; 10(7): 1206–11.

    PubMed  CAS  Google Scholar 

  19. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure: Collaborative Transplant Study. Kidney Int 1998; 53(1): 217–22.

    Article  PubMed  CAS  Google Scholar 

  20. Mange KC, Cizman B, Joffe M, et al. Arterial hypertension and renal allograft survival. JAMA 2000; 283(5): 633–8.

    Article  PubMed  CAS  Google Scholar 

  21. Ponticelli C, Montagnino G, Aroldi A, et al. Hypertension after renal transplantation. Am J Kidney Dis 1993; 21(5 Suppl. 2): 73–8.

    PubMed  CAS  Google Scholar 

  22. Crook ED. Diabetic renal disease in African Americans. Am J Med Sci 2002 Feb; 323(2): 78–84.

    Article  PubMed  Google Scholar 

  23. Cosio FG, Pelletier RP, Sedmak DD, et al. Renal allograft survival following acute rejection correlates with blood pressure levels and histopathology. Kidney Int 1999; 56(5): 1912–9.

    Article  PubMed  CAS  Google Scholar 

  24. Cosio FG, Pelletier RP, Pesavento TE, et al. Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. Kidney Int 2001; 59(3): 1158–64.

    Article  PubMed  CAS  Google Scholar 

  25. Sanders CE, Curtis JJ. Role of hypertension in chronic renal allograft dysfunction. Kidney Int Suppl 1995; 52: S43–7.

    PubMed  Google Scholar 

  26. Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 2001; 72(6 Suppl.): S5–8.

    Article  PubMed  CAS  Google Scholar 

  27. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11(9): 1735–43.

    PubMed  CAS  Google Scholar 

  28. Weir MR. Blood pressure management in the kidney transplant recipient. Adv Chronic Kidney Dis 2004 Apr; 11(2): 172–83.

    Article  PubMed  Google Scholar 

  29. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206–52.

    Article  PubMed  CAS  Google Scholar 

  30. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29(2): 641–50.

    Article  PubMed  CAS  Google Scholar 

  31. Stigant CE, Cohen J, Vivera M, et al. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35(1): 58–63.

    Article  PubMed  CAS  Google Scholar 

  32. de Groen PC. Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin Proc 1988; 63(10): 1012–21.

    PubMed  Google Scholar 

  33. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63(3): 331–8.

    Article  PubMed  CAS  Google Scholar 

  34. Crook ED, Thallapureddy A, Migdal S, et al. Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? Am J Med Sci 2003; 325(6): 340–8.

    Article  PubMed  Google Scholar 

  35. Wissing KM, Abramowicz D, Broeders N, et al. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 2000; 70(3): 464–72.

    Article  PubMed  CAS  Google Scholar 

  36. Isoniemi H, Nurminen M, Tikkanen MJ, et al. Risk factors predicting chronic rejection of renal allografts. Transplantation 1994; 57(1): 68–72.

    Article  PubMed  CAS  Google Scholar 

  37. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73(5): 775–82.

    Article  PubMed  CAS  Google Scholar 

  38. Del Castillo D, Cruzado JM, Manel Diaz J, et al. The effects of hyperlipidaemia on graft and patient outcome in renal transplantation. Nephrol Dial Transplant 2004; 19 Suppl. 3: 67–71.

    Google Scholar 

  39. Vollmer E, Bosse A, Bogeholz J, et al. Apolipoproteins and immunohistological differentiation of cells in the arterial wall of kidneys in transplant arteriopathy: morphological parallels with atherosclerosis. Pathol Res Pract 1991; 187(8): 957–62.

    Article  PubMed  CAS  Google Scholar 

  40. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation: a pilot study. Transplantation 1996; 61(10): 1469–74.

    Article  PubMed  CAS  Google Scholar 

  41. Kasiske BL, Heim-Duthoy KL, Singer GG, et al. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 2001; 72(2): 223–7.

    Article  PubMed  CAS  Google Scholar 

  42. Holdaas H, Jardine AG, Wheeler DC, et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int 2001; 60(5): 1990–7.

    Article  PubMed  CAS  Google Scholar 

  43. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20): 1301–7.

    Article  PubMed  CAS  Google Scholar 

  44. Taylor DO, Thompson JA, Hastillo A, et al. Hyperlipidemia after clinical heart transplantation. J Heart Transplant 1989; 8(3): 209–20.

    PubMed  CAS  Google Scholar 

  45. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events trial investigators. N Engl J Med 1996; 335(14): 1001–9.

    Article  PubMed  CAS  Google Scholar 

  46. Cutts JL, Scallen TJ, Watson J, et al. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989; 139(3): 550–7.

    Article  PubMed  CAS  Google Scholar 

  47. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6(12): 1399–402.

    Article  PubMed  CAS  Google Scholar 

  48. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7(6): 687–92.

    Article  PubMed  CAS  Google Scholar 

  49. Regazzi MB, Iacona I, Campana C, et al. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A. Transplant Proc 1994; 26(5): 2644–5.

    PubMed  CAS  Google Scholar 

  50. Akhlaghi F, Ashley J, Keogh A, et al. Cyclosporine plasma unbound fraction in heart and lung transplantation recipients. Ther Drug Monit 1999; 21(1): 8–16.

    Article  PubMed  CAS  Google Scholar 

  51. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebocontrolled trial. Lancet 2003; 361(9374): 2024–31.

    Article  PubMed  CAS  Google Scholar 

  52. Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41(3): 565–70.

    Article  PubMed  CAS  Google Scholar 

  53. Fellstrom B, Holdaas H, Jardine AG, et al. Effect of fluvastatin on renal end points in the Assessment of LEscol in Renal Transplant (ALERT) trial. Kidney Int 2004 Oct; 66(4): 1549–55.

    Article  PubMed  Google Scholar 

  54. Stojanovic I, Vrtovec B, Radovancevic B, et al. Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-year follow-up. J Heart Lung Transplant 2005 Sep; 24(9): 1235–8.

    Article  PubMed  Google Scholar 

  55. Bilchick KC, Henrikson CA, Skojec D, et al. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J 2004 Aug; 148(2): 200–10.

    Article  PubMed  CAS  Google Scholar 

  56. Kobashigawa JA. Statins as immunosuppressive agents. Liver Transpl 2001; 7(6): 559–61.

    Article  PubMed  CAS  Google Scholar 

  57. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 May 16; 285(19): 2486–97.

    Article  Google Scholar 

Download references

Acknowledgments

The first and second authors have contributed equally to this paper.

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Wayne State University School of Medicine, Detroit, Michigan, USA

    Jose-Marie El-Amm, Abdolreza Haririan &  Errol D. Crook

  2. John D. Dingell Veteran Affairs Medical Center, Detroit, Michigan, USA

    Errol D. Crook

Authors
  1. Jose-Marie El-Amm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdolreza Haririan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Errol D. Crook
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Errol D. Crook.

Rights and permissions

Reprints and permissions

About this article

Cite this article

El-Amm, JM., Haririan, A. & Crook, E.D. The Effects of Blood Pressure and Lipid Control on Kidney Allograft Outcome. Am J Cardiovasc Drugs 6, 1–7 (2006). https://doi.org/10.2165/00129784-200606010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200606010-00001

Keywords

Search

Navigation